Invasive recurrence risk explored for HER2+ breast cancer

This article originally appeared here.
Share this content:
Invasive Recurrence Risk Examined for HER2+ Breast CA
Invasive Recurrence Risk Examined for HER2+ Breast CA

(HealthDay News) -- For patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer, distant invasive recurrence is low for T1a tumors and is higher for T1b tumors, especially those with T1b tumors reported at 1.0 cm, according to a study published online June 2 in the Journal of Clinical Oncology.

Lou Fehrenbacher, M.D., from Kaiser Permanente in Northern California, and colleagues investigated the risk of invasive recurrence among 234 patients with small, node-negative HER2+ breast cancer. Participants with T1a+bN0M0 tumors, identified from a large, integrated health care system, had a median follow-up of 5.8 years.

The researchers identified 15 invasive recurrences, of which 47 percent were local/regional only. The five-year distant invasive relapse-free interval (RFI) was 98.2 percent among 171 T1ab patients not treated with adjuvant trastuzumab or chemotherapy; 99.0 percent for T1a patients; and 97.0 percent for T1b patients. For T1a, T1b, and T1b tumors reported at 1.0 cm, the local/regional plus distant five-year invasive RFI was 97.0, 91.9, and 89.4 percent, respectively. About one-quarter (24 percent) of the T1ab cohort comprised T1b tumors reported at 1.0 cm, which accounted for 61 percent of the cohort total tumor volume and three-quarters of distant recurrences (75 percent). The invasive RFI was lower for T1b 1.0 cm tumors (84.5 percent) than for T1a tumors (97.4 percent; P = 0.009).

"Potential risk differences for T1a and T1b, including the 1.0 cm tumors, should be considered when making treatment decisions," the authors write.

Full Text (subscription or payment may be required)

You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs